Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Updated Safety and Efficacy Data from AG-348, AG-519 and Completed Dose Escalation Portion of AG-120 Study to be Highlighted in Oral and Poster Presentations - - Company to Host Investor...
-
– Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End – ...
-
CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
-
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
-
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
-
CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common...
-
CAMBRIDGE, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $150...
-
CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
-
CAMBRIDGE, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
-
CAMBRIDGE, Mass., Aug. 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...